Relay Therapeutics, Inc. (RLAY)
Nasdaq: RLAY · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Feb 26, 2026 | Feb 26, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 24, 2022 | Mar 25, 2021 | · |
| Revenue | 15,355 | 10,007 | 25,546 | 1,381 | 3,029 | 82,654 | · |
| Research and development | 261,383 | 319,089 | 330,018 | 246,355 | 172,650 | 99,862 | 70,306 |
| General and administrative | 56,710 | 76,592 | 74,950 | 65,978 | 57,386 | 38,588 | 13,742 |
| Total operating expenses | 318,093 | 382,475 | 398,546 | 300,656 | 367,727 | 138,450 | 84,048 |
| Operating income | -302,738 | -372,468 | -373,000 | -299,275 | -364,698 | -55,796 | -84,048 |
| Interest and investment income | 27,035 | 34,746 | 31,045 | 8,786 | 830 | 3,400 | 8,801 |
| Other income (expense), net | 26,259 | 34,760 | 31,027 | 8,766 | 826 | 3,384 | 8,743 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income from continuing operations | · | · | · | · | -363,872 | -230,201 | -75,305 |
| Net income | -276,479 | -337,708 | -341,973 | -290,509 | -363,872 | -52,412 | -75,305 |
| Net income to common shareholders | · | · | · | · | -363,872 | -230,201 | -75,305 |
| Earnings per share, basic | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | · |
| Earnings per share, diluted | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | · |
| Earnings per share, basic and diluted | · | · | · | · | -3.82 | -5.40 | -21.82 |
| Weighted average shares, basic | 171,586,558 | 142,867,844 | 122,576,527 | 112,233,649 | 95,136,719 | 42,619,582 | · |
| Weighted average shares, diluted | · | · | · | 112,233,649 | 95,136,719 | 42,619,582 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 95,136,719 | 42,619,582 | 3,450,500 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitIncome from continuing operations profit from the businesses it keeps
us-gaap:IncomeLossFromContinuingOperationsNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted